Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL3580522 Target Snapshot

Programmed cell death 1 ligand 1 · SINGLE PROTEIN · Homo sapiens

1,536Compounds
169Assays
1Approved Drugs
1,897.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Programmed cell death 1 ligand 1 shows approved-linked disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block. 13 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt Q9NZQ7. Start with neoplasm, then reuse UniProt Q9NZQ7 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with neoplasm, then reuse UniProt Q9NZQ7 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 13 linked drugs
Open source guide
Disease program
neoplasm

Programmed cell death 1 ligand 1 shows approved-linked disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block. 13 linked drugs remain visible in the same block.

Start review with neoplasm because it currently carries approved-linked support. Linked drugs include ADEBRELIMAB, ATEZOLIZUMAB, AVELUMAB, BINTRAFUSP ALFA. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 13 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Programmed cell death 1 ligand 1 as ChEMBL target CHEMBL3580522, mapped to UniProt Q9NZQ7. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Programmed cell death 1 ligand 1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL3580522
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q9NZQ7
Programmed cell death 1 ligand 1
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Programmed cell death 1 ligand 1 is the right protein anchor across sources, using UniProt Q9NZQ7 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why neoplasm is currently framed as approved-linked support. It currently carries 13 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelProgrammed cell death 1 ligand 1
UniProt AccessionQ9NZQ7
Component TypeProtein
Sequence Length290 aa

Programmed cell death 1 ligand 1

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Programmed cell death 1 ligand 1, mapped to UniProt Q9NZQ7. Sequence length is 290 aa.

Mapped IDQ9NZQ7
Review nameProgrammed cell death 1 ligand 1
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Programmed cell death 1 ligand 1 shows approved-linked disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
neoplasm
13 linked drugs · 13 direct · 13 efficacy
Linked drugADEBRELIMAB
Linked drugATEZOLIZUMAB
Linked drugAVELUMAB
Linked drugBINTRAFUSP ALFA
Approved-linked Approved
non-small cell lung carcinoma
9 linked drugs · 9 direct · 9 efficacy
Linked drugADEBRELIMAB
Linked drugATEZOLIZUMAB
Linked drugAVELUMAB
Linked drugBINTRAFUSP ALFA
Approved-linked Approved
breast cancer
7 linked drugs · 7 direct · 7 efficacy
Linked drugADEBRELIMAB
Linked drugATEZOLIZUMAB
Linked drugAVELUMAB
Linked drugBINTRAFUSP ALFA
Approved-linked Approved
cancer
7 linked drugs · 7 direct · 7 efficacy
Linked drugADEBRELIMAB
Linked drugATEZOLIZUMAB
Linked drugAVELUMAB
Linked drugDANBURSTOTUG
Approved-linked Approved
small cell lung carcinoma
7 linked drugs · 7 direct · 7 efficacy
Linked drugADEBRELIMAB
Linked drugATEZOLIZUMAB
Linked drugAVELUMAB
Linked drugBINTRAFUSP ALFA
Approved-linked Approved
head and neck squamous cell carcinoma
6 linked drugs · 6 direct · 6 efficacy
Linked drugADEBRELIMAB
Linked drugATEZOLIZUMAB
Linked drugAVELUMAB
Linked drugBINTRAFUSP ALFA
Source · ChEMBL drug mechanism + indication proxy
Review Cue

How to read disease relevance

Start review with neoplasm because it currently carries approved-linked support. Linked drugs include ADEBRELIMAB, ATEZOLIZUMAB, AVELUMAB, BINTRAFUSP ALFA. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseneoplasm
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

1
Approved
Assay Mix

Activity Type Distribution

IC501,767.0
KI3.0
EC504.0
KD123.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL4473436 10.72 Kd 0.019 Preclinical
CHEMBL5412235 9.71 Ki 0.195 Preclinical
CHEMBL4456990 9.7 Kd 0.2 Preclinical
CHEMBL4578475 9.68 Kd 0.21 Preclinical
CHEMBL5413429 9.68 IC50 0.21 Preclinical
CHEMBL4460716 9.54 Kd 0.29 Preclinical
CHEMBL5398154 9.32 IC50 0.48 Preclinical
CHEMBL5207924 9.15 Kd 0.7 Preclinical
CHEMBL4081869 9.0 IC50 1.0 Preclinical
CHEMBL4776700 9.0 IC50 1.0 Preclinical
Distribution

pChEMBL Value Distribution

70
5.0
17
5.5
314
6.0
249
6.5
136
7.0
44
7.5
14
8.0
9
8.5
6
9.0
5
9.5
pChEMBL
Assay Landscape

Assay Landscape

169
Total Assays
811
Tested Compounds
1
Assay Types
Binding — 169 assays, 811 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 80 780 6.3
cell-based format 67 12 7.0
assay format 14 17 5.9
subcellular format 5 0
tissue-based format 2 1 7.3
cell membrane format 1 1 4.0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine